Trial reportAmerican journal of respiratory and critical care medicine2007
Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma.
Trial report in American journal of respiratory and critical care medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03207620 (Interrelation Between Bronchial Asthma and Smoking), which is not on this map. Cited by 141 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interrelation Between Bronchial Asthma and Smoking
Who cites it
141 citing papers in PubMed, 5 syntheses or guidelines pooled it, 447 citations in OpenAlex.
- Association between vitamin A and asthma: A meta-analysis with trial sequential analysis.Frontiers in pharmacology · 2023Pooled it
- Risk factors for asthma exacerbations during pregnancy: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022Pooled it
- Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.The Cochrane database of systematic reviews · 2012Pooled it
- Effect of tumor necrosis factor-α antagonism in asthma: a meta-analysis of the published literature.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2011Pooled it
- Triple therapy for COPD: a crude analysis from a systematic review of the evidence.Therapeutic advances in respiratory diseasePooled it
- Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.Journal of immunology research · 2023Trial
- Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma.The New England journal of medicine · 2022Trial
- Exacerbation-prone asthma in the context of race and ancestry in Asthma Clinical Research Network trials.The Journal of allergy and clinical immunology · 2019Trial
- Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.Respiratory research · 2019Trial
- Race is associated with differences in airway inflammation in patients with asthma.The Journal of allergy and clinical immunology · 2017Trial
- Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2015Trial
- Smoking decreases the response of human lung macrophages to double-stranded RNA by reducing TLR3 expression.Respiratory research · 2013Trial
- A large subgroup of mild-to-moderate asthma is persistently noneosinophilic.American journal of respiratory and critical care medicine · 2012Trial
- Impact of race on asthma treatment failures in the asthma clinical research network.American journal of respiratory and critical care medicine · 2011Trial
- Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma.The Journal of allergy and clinical immunology · 2010Trial
- Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial.PharmacoEconomics · 2010Trial
- Duration of treatment with inhaled corticosteroids in nonasthmatic eosinophilic bronchitis: a randomized open label trial.Therapeutic advances in respiratory diseaseTrial
- Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial).Canadian respiratory journalTrial
- Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial.Canadian respiratory journalTrial
- Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026Review
81 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors at 8 institutions in 1 country.
Funding
Abstract
rationaleOne-quarter to one-third of individuals with asthma smoke, which may affect response to therapy and contribute to poor asthma control.
objectivesTo determine if the response to an inhaled corticosteroid or a leukotriene receptor antagonist is attenuated in individuals with asthma who smoke.
methodsIn a multicenter, placebo-controlled, double-blind, double-dummy, crossover trial, 44 nonsmokers and 39 light smokers with mild asthma were assigned randomly to treatment twice daily with inhaled beclomethasone and once daily with oral montelukast. MEASUREMENTS AND MAIN
resultsPrimary outcome was change in prebronchodilator FEV(1) in smokers versus nonsmokers. Secondary outcomes included peak flow, PC(20) methacholine, symptoms, quality of life, and markers of airway inflammation. Despite similar FEV(1), bronchodilator response, and sensitivity to methacholine at baseline, subjects with asthma who smoked had significantly more symptoms, worse quality of life, and lower daily peak flow than nonsmokers. Adherence to therapy did not differ significantly between smokers and nonsmokers, or between treatment arms. Beclomethasone significantly reduced sputum eosinophils and eosinophil cationic protein (ECP) in both smokers and nonsmokers, but increased FEV(1) (170 ml, p = 0.0003) only in nonsmokers. Montelukast significantly increased a.m. peak flow in smokers (12.6 L/min, p = 0.002), but not in nonsmokers.
conclusionsIn subjects with mild asthma who smoke, the response to inhaled corticosteroids is attenuated, suggesting that adjustments to standard therapy may be required to attain asthma control. The greater improvement seen in some outcomes in smokers treated with montelukast suggests that leukotrienes may be important in this setting. Larger prospective studies are required to determine whether leukotriene modifiers can be recommended for managing asthma in patients who smoke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.